FDA, 27 DEC 2025 — The FDA has released its long-awaited Draft Guidance on Current Good Manufacturing Practice (CGMP) for Medical Gases, signaling a major shift from “one-size-fits-all” drug rules to a tailored regulatory framework.,
Medical gas manufacturers have operated under general drug regulations (21 CFR Parts 210 and 211) that were designed for pills and liquids, often resulting in inefficient compliance processes. The new guidance, released to support the newly established 21 CFR Part 213, provides specific recommendations for the manufacturing, processing, packing, and holding of medical gases.
This publication triggers a clear compliance timeline for the industry.
TIMELINE FOR MANUFACTURERS: NAVIGATING THE FDA COMPLIANCE PROCESS FOR MEDICAL GAS AND CGMP STANDARDS
The guidance outlines two critical compliance dates that manufacturers must mark on their calendars:
- December 18, 2025: New CGMP rules (Part 213) generally apply to medical gas manufacturers.
- February 2, 2026: Compliance deadline for Combination Products (medical gases combined with device constituent parts).
IMPACTED AREAS: WHAT MANUFACTURERS NEED TO KNOW ABOUT 21 CFR PARTS 210 AND 211
The guidance introduces strict controls that specifically impact manufacturers of medical devices (cylinders, valves, regulators) and combination products.
- Combination Products & The “Streamlined Approach” If you manufacture a medical gas that includes a device constituent part (e.g., a specialized valve or delivery mechanism), you are subject to 21 CFR Part 4. The guidance confirms that manufacturers can use a “streamlined approach” to demonstrate compliance:
- You do not need to maintain two separate full quality systems.
- By complying with the Medical Gas CGMP (Part 213), you largely satisfy the requirements, provided you also address specific device design controls.
- Mandatory Safety Testing (The “Dead-Ring” Test) The FDA is increasing scrutiny on container safety to prevent leaks and structural failures.
- Leak Testing: Manufacturers must now leak test every container at the time of fill and after filling but prior to release.
- Hammer Test: For steel cylinders, the guidance recommends a “hammer or dead-ring test.” A clear bell tone indicates a clean cylinder; a dull ring suggests internal corrosion requiring further investigation.
- No Soap Allowed: The use of soap solutions for leak detection is discouraged as they can corrode valve stems. Specialized leak detection solutions must be used.
- Strict Labeling & Connection Standards To prevent fatal gas mix-ups (e.g., connecting Nitrogen instead of Oxygen), the guidance imposes new physical and visual standards:
- 360° Labeling: Portable cryogenic containers must feature a wraparound label allowing the gas name (e.g., “Oxygen USP”) to be read from any angle.
- No Adapters: The guidance effectively bans the use of adapters for end-users to circumvent gas-specific connections. Portable cryogenic containers must have permanently attached, gas-specific outlet connections.
- Supplier Qualification & Audits Manufacturers relying on certificates of analysis (COA) from suppliers must now establish a robust program to verify the supplier’s reliability. This includes periodic testing and audits, meaning device component suppliers (e.g., valve manufacturers) may face increased audit requests from their gas-filling partners.
RESOURCES
- Draft Guidance: Medical Gases Current Good Manufacturing Practice
- Regulation: 21 CFR Part 213
Next Steps Manufacturers involved in the supply chain whether filling gas or producing the cylinders and valves should immediately review Section VI of the guidance to assess their current “Incoming Material” controls against these new standards.